Risk assessment of carcinogens and threshold range, Part II;Die risikobewertung von kanzerogenen und die wirkungsschwelle, teil II

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 49, Issue 8, 2006, Pages 818-823

  Neumann, H G ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

CHEMICALLY INDUCED DISORDER; DIFFERENTIAL THRESHOLD; DOSE RESPONSE; EVIDENCE BASED MEDICINE; GERMANY; HUMAN; METHODOLOGY; NEOPLASM; NOTE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

CARCINOGENS; DATA INTERPRETATION, STATISTICAL; DIFFERENTIAL THRESHOLD; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 33747043931     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-006-0012-x     Document Type: Note

References (28)

1. Neumann HG (2006) Die Risikobewertung von Kanzerogenen und die Wirkungsschwelle. Teil I. Bundesgesundheitsblatt 49:665-675
2. Farmer JH, Kodell RL, Greenman DL, Shaw GW (1979) Dose and time response models for the incidence of bladder and liver neoplasms in mice fed 2-acetylaminofluorene continuously. J Environm Pathol Toxicol 3: 55-68
3. Jackson CD, Weis C, Shellenberger TE (1980) Tissue binding of 2-acetylaminofluorene in BALB/c and C57Bl/6 mice during chronic oral administration. Chem-Biol Interactions 32: 63-81
4. Poirier MC, Fullerton NF, Kinouchi T et al. (1991) Comparison between DNA adduct formation and tumorigenicity in livers and bladders of mice chronically fed 2-acetylaminofluorene. Carcinogenesis 12: 895-900
5. Travis CC, Zeng C, Nicholas J (1996) Biological model of ED01 hepatocarcinogenesis. Toxicol Appl Pharmacol 140: 19-29
6. Waddell WJ (2003) Thesholds of carcinogenicity in the EDO1 study. Toxicol Sci 72: 158-163
7. Haseman JK (2003) An alternative perspective: a critical evaluation of the Waddell threshold extrapolation model in chemical carcinogenesis. Toxicol Pathol 31: 712-713
8. Rozman KK (2003) Thresholds in carcinogenicity in EDO1 study. Toxicol. Sci 75: 224-225
9. Maugh II TH (1978) Chemical carcinogens: how dangerous are low doses. Science 202: 37-41
10. Hooper NK, Harris RH, Ames BN (1979) Letters. Chemical carcinogens. Science 203: 602-603
11. Baur H, Neumann HG (1980) Correlation of nucleic acid binding by metabolites of trans-4-aminostilbene derivatives with tissue specific acute toxicity and carcinogenicity in rats. Carcinogenesis 1: 877-885
12. Lutz WK (1990) Dose response relationship and low dose extrapolation in chemical carcinogenesis, Carcinogenesis 11: 1243-1247
13. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
14. Mantel N, Schneiderman MA (1975) Estimating "safe" levels, a hazardous undertaking. Cancer Res 35: 1379-1386
15. Clayson DB (1978) Overview, myth and speculation. J Environm Pathol Toxicol 2: 1-8
16. Wolf FJ (1980) Effect of overloading pathways on Toxicity. J Environ Pathol Toxicol 3: 113-134
17. Fukushima S, Wanibuchi H, Morimura K et al. (2003) Lack of initiation in rat liver of low doses of 2-amino-3,8,dimethylimidazo[4,5-f]quinoxalin. Cancer Lett 191: 35-40
18. Greim H, Göggelmann W, Hesse S et al. (1981) How relevant are high doses in mutagenicity and carcinogenicity studies in animals. Progress in Mutation Res 2: 129-147
19. Lutz WK, Schlatter C (1978) Extrapolation of carcinogenicity data to low doses with a dose-response study of the binding of benzo(a)pyrene to rat liver DNA. Arch Toxicol Suppl 1: 369-371
20. Ramsey JC, Gehring PJ (1980) Application of pharmacokinetic principles in practice. Fed Proc 39: 60-65
21. Lutz WK, Kopp-Schneider A (1999) Threshold dose response for tumor induction by genotoxic carcinogens modeled via cell-cycle delay. Toxicol Sci 49: 110-115
22. Hart RW, Frame LT (1996) Toxicological defense mechanisms and how they may affect the nature of dose-response relationships. Belle Newsletter 5: 1-16
23. Hagiwara A, Matsuda T, Tsmsno S et al. (1996) Dose-related increases in quantitative values for altered hepatic foci and cytochrome p 450 levels in the liver of rats exposed to phenobarbital in a medium term bioassay. Cancer Lett 110: 155-162
24. Kitano M, Ichihara T, Matsuda T et al. (1998) Presence of a threshold for promoting effects of phenobarbital on diethylnitrosamine-induced hepatic foci in the rat. Carcinogenesis 19: 1475-1480
25. Bitsch A, Deubelbeiss C, Greiner A (1999) c-fos gene expression in rat liver is induced by phenobarbital. Cancer Lett 135: 215-222
26. Park CN, Snee ED (1983) Quantitative risk assessment: state of the art for carcinogenesis. Fund Appl Toxicol 3: 320-333
27. Oesch F, Herrero ME, Hengstler JG et al. (2000) Metabolic detoxification; implications for thresholds. Toxicol Pathol 28: 382-387
28. Edler L, Porti CJ, Kopp-Schneider A (1994) Zur Existenz von Schwellenwerten: Wissenschaftliche Methode oder statistisches Artefakt in der Risikoabschätzung. Zbl Arbeitsmed 44: 16-21